Höhle S, Spitznagel H, Rascher W, Culman J, Unger T
Department of Pharmacology, University of Kiel, Germany.
Eur J Pharmacol. 1995 Mar 14;275(3):277-82. doi: 10.1016/0014-2999(95)00005-6.
Stimulation of angiotensin II AT2 receptors has been shown to inhibit AT1 receptor-mediated actions in peripheral tissues. The role of AT2 receptors in the central actions of angiotensin is not well understood. In the present study, plasma vasopressin levels and water intake in response to intracerebroventricular angiotensin II (10 pmol) were determined after intracerebroventricular pretreatment with PD 123177 (1-(4-amino-3-methylphenyl)methyl-5-diphenylacetyl-4,5,6,7-tetrahy dro-1H- imidazo[4,5-c]pyridine-6-carboxylic acid-2HCl), a selective AT2 receptor antagonist (10, 100 and 1000 pmol), or with losartan (2-n-butyl-4-chloro-5-hydroxy-methyl-1-2'-(1H-tetrazole-5-yl)biphenyl-4- yl)methylimidazole, potassium salt), a specific AT1 receptor antagonist (0.2, 2 and 10 nmol). Blood samples for vasopressin determination were drawn 90 s after angiotensin II injection and the drinking response was determined in a time interval of 10 min after intracerebroventricular angiotensin II. Losartan at a dose of 2 nmol or higher completely prevented vasopressin release and drinking response to angiotensin II. The drinking response was already attenuated after pretreatment with the lowest dose of losartan. In contrast, PD 123177 potentiated the angiotensin II-induced vasopressin release (39.7 +/- 2.7 pg/ml after 1000 pmol PD 123177 vs. 21.3 +/- 2.9 pg/ml in vehicle-pretreated controls, P < 0.05). The dipsogenic response to angiotensin II was also potentiated by PD 123177 (9.5 +/- 0.7 ml after 1000 pmol PD 123177 vs. 5.1 +/- 1.3 ml in vehicle-pretreated controls, P < 0.05). Our results suggest that the angiotensin II-induced vasopressin release and drinking, mediated by central AT1 receptors, are under inhibitory control by central AT2 receptors.
已表明刺激血管紧张素II AT2受体可抑制外周组织中AT1受体介导的作用。AT2受体在血管紧张素中枢作用中的角色尚未完全明确。在本研究中,在用选择性AT2受体拮抗剂PD 123177(1-(4-氨基-3-甲基苯基)甲基-5-二苯乙酰基-4,5,6,7-四氢-1H-咪唑并[4,5-c]吡啶-6-羧酸-2HCl)(10、100和1000 pmol)或特异性AT1受体拮抗剂氯沙坦(2-正丁基-4-氯-5-羟甲基-1-[2'-(1H-四氮唑-5-基)联苯-4-基]甲基咪唑钾盐)(0.2、2和10 nmol)进行脑室内预处理后,测定脑室内注射血管紧张素II(10 pmol)后的血浆血管加压素水平和水摄入量。在注射血管紧张素II后90秒采集用于测定血管加压素的血样,并在脑室内注射血管紧张素II后的10分钟时间间隔内测定饮水反应。剂量为2 nmol或更高的氯沙坦完全抑制了血管加压素释放以及对血管紧张素II的饮水反应。在用最低剂量的氯沙坦预处理后,饮水反应就已减弱。相反,PD 123177增强了血管紧张素II诱导的血管加压素释放(1000 pmol PD 123177处理后为39.7±2.7 pg/ml,而载体预处理对照组为21.3±2.9 pg/ml,P<0.05)。PD 123177也增强了对血管紧张素II的致渴反应(1000 pmol PD 123177处理后为9.5±0.7 ml,而载体预处理对照组为5.1±1.3 ml,P<0.05)。我们的结果表明,由中枢AT1受体介导的血管紧张素II诱导的血管加压素释放和饮水受中枢AT2受体的抑制性调控。